SARS-CoV-2 Nucleocapsid Protein Surface Display for Diagnostic Variant Mapping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rapid antigen tests for COVID-19 face challenges in accurately detecting SARS-CoV-2 nucleocapsid protein mutations due to emerging viral variants, which can affect the binding affinity of antibodies, leading to reduced test accuracy and false negatives.
Innovation Solution
A method involving mammalian surface-display of the SARS-CoV-2 nucleocapsid protein with a site-saturated mutational library, combined with deep mutational scanning, to measure the binding affinity of antibodies to all possible nucleocapsid protein mutations, generating a comprehensive map of epitopes and escape mutations, thereby evaluating the performance of diagnostic tests against various viral variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If rapid antigen tests use fixed antibodies to detect nucleocapsid protein, then test simplicity and speed are maintained, but test accuracy deteriorates when viral mutations occur
Solution Approach 1:
The patent implements a dynamic test system where antibody panels are updated based on monitored viral mutations. The system transitions from static single-antibody tests to dynamic multi-antibody panels that adapt to emerging variants, maintaining both speed and accuracy through structured flexibility in the detection system
Solution Approach 2:
The patent changes the parameter of antibody diversity by implementing panels with multiple antibodies having different epitope specificities. This parameter change allows the system to maintain binding affinity across various viral mutations while preserving the rapid detection capability through automated panel-based testing
2Reliability
If antibody panels with multiple specificities are implemented, then test accuracy against variants is improved, but test complexity increases
Solution Approach 1:
The patent segments the detection function into multiple independent antibody components, each targeting specific epitopes. This segmentation allows systematic evaluation of individual antibody performances and facilitates modular updates to the panel composition without redesigning the entire test system
Solution Approach 2:
The patent creates a universal antibody panel framework that can detect multiple viral variants through a single integrated test. The multi-functional panel simultaneously performs detection of wild-type and variant strains, eliminating the need for separate tests for different variants and reducing overall system complexity
3Loss of information
If comprehensive mutational scanning is performed, then understanding of escape mutations is improved, but time and resources required increase
Solution Approach 1:
The patent performs preliminary comprehensive mutational scanning to establish a reference database of escape mutations before clinical deployment. This advance preparation creates a knowledge base that enables rapid interpretation of test results without requiring time-consuming sequential testing of each mutation, thus reducing ongoing testing time while maintaining comprehensive information
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a robust method to predict the performance of rapid antigen tests against current and future variants, ensuring continued accuracy in detecting COVID-19 infections by identifying potential escape mutations and validating test performance with sequence-confirmed clinical samples.
Implementation Method 1
an N-terminal signal peptide sequence for translocation of the peptide across a cell membrane
Implementation Method 2
a transmembrane domain sequence for insertion into a cell membrane C-terminal to the coronavirus nucleocapsid sequence
Implementation Method 3
contacting binding agents used in diagnostic test with libraries of cell surface expressed protein variants to analyze binding affinity
Data Source
AI summary
This disclosure relates to libraries of recombinant protein variants expressed on the surface of cells from expression constructs and uses in methods analyzing the impact of one or more mutations on affinity binding to specific binding agents. In certain embodiments, this disclosure relates to methods of contacting binding agents used in diagnostic test with libraries of cell surface expressed protein variants to analyze binding affinity. In certain embodiments, the protein variants are expressed on the exterior of cells containing intracellular nucleic acids with barcodes that correlate to specific amino acid variants sequences.